Trends in enzyme-inducing antiseizure medication use: A retrospective analysis among adults with epilepsy
Epilepsy & Behavior · 2024
DOI: 10.1016/j.yebeh.2024.109662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2024. Verfasst von Revital Gandelman-Marton und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, Shamir-Assaf Harofeh Medical Center, Zerifin, Israel; Faculty of Medicine, Tel Aviv University, Israel. Electronic address: rev…. Hauptthemen laut MEDLINE: Epilepsy, Epilepsies, Partial. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Enzyme-inducing antiseizure medications (EIASMs) were associated with drug interactions and long-term adverse effects. Therefore, it was suggested that epilepsy treatment should be started with non-EIASMs, and in patients treated with EIASMs, replacement with non-EIASMs should be evaluated OBJECTIVE: To assess potent EIASM use among patients with epilepsy at their first visit in our epilepsy outpatient clinic. METHODS: We retrospectively reviewed the computerized database and the medical records of all the patients who had their first visit in our outpatient epilepsy clinic during a 10-year period (2012-2021). Of 730 patients with ASM treated epilepsy, 243 (33%) were receiving potent EIASMs. RESULTS: The annual potent EIASM use decreased from 35.1 % in 2012 to 11.8 % in 2021. Most of the patients who received potent EIASM had their first visit during 2012-2015 compared to the following years (56.8 % vs 43.2 %) (p = 0.0001). Patients with epilepsy receiving potent EIASMs were older (44.3 vs 34.7) (p = 0.0001), more likely men (60.9 % vs 47.2 %) (p = 0.001), with longer disease duration (13 vs 9.3 y) (p = 0.0001), higher rate of neuropsychiatric comorbidity (37 % vs 27.9 %) (p = 0.014), and were treated with more ASMs (1.6 vs 1.3) (p = 0.0001) compared to patients receiving non-EIASMs. CONCLUSIONS: Potent EIASM use has been declining over the past decade. Additional efforts to further decrease EIASM use should be exerted among all patients with ASM-treated epilepsy, with emphasis on men with focal epilepsy and epilepsy duration > 10 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Department, Shamir-Assaf Harofeh Medical Center, Zerifin, Israel; Faculty of Medicine, Tel Aviv University, Israel. Electronic address: revitalgm@hotmail.com.
- Neurology Department, Shamir-Assaf Harofeh Medical Center, Zerifin, Israel; Faculty of Medicine, Tel Aviv University, Israel.
Zitieren
APA
Gandelman-Marton, R., & Theitler, J. (2024). Trends in enzyme-inducing antiseizure medication use: A retrospective analysis among adults with epilepsy. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2024.109662
Vancouver
Gandelman-Marton R, Theitler J. Trends in enzyme-inducing antiseizure medication use: A retrospective analysis among adults with epilepsy. Epilepsy & Behavior. 2024. doi:10.1016/j.yebeh.2024.109662
BibTeX
@article{GandelmanMarton2024,
author = {Gandelman-Marton, Revital and Theitler, Jacques},
title = {Trends in enzyme-inducing antiseizure medication use: A retrospective analysis among adults with epilepsy},
journal = {Epilepsy & Behavior},
year = {2024},
doi = {10.1016/j.yebeh.2024.109662}
}
EUVIMED